A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:
• Male or female participant aged 18 to 75 years(inclusive)at the time of informed consent.
• Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.
• Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization
Locations
Other Locations
China
Hospital of Dermatology, Chinese Academy of Medical Sciences
RECRUITING
Nanjing
Contact Information
Primary
Lu Qianjin
qianlu5860@gmail.com
+8613787097676
Time Frame
Start Date: 2026-03-18
Estimated Completion Date: 2027-07-30
Participants
Target number of participants: 375
Treatments
Experimental: Group 1:WD-890
Drug:WD-890~WD-890 tablet will be administered orally.
Placebo_comparator: Group 2: Placebo
Drug: Placebo~Placebo tablet will be administered orally.
Related Therapeutic Areas
Sponsors
Leads: Zhejiang Wenda Pharma Technology LTD.